<DOC>
	<DOCNO>NCT02933853</DOCNO>
	<brief_summary>A Trial Investigating Pharmacokinetic Pharmacodynamic Properties Faster-acting Insulin Aspart Subjects Type 2 Diabetes Mellitus</brief_summary>
	<brief_title>A Trial Investigating Pharmacokinetic Pharmacodynamic Properties Faster-acting Insulin Aspart Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Male female , age 18−70 year ( inclusive ) time sign informed consent . The total number subject age 65−70 year ( inclusive ) must NOT exceed 15 . Subjects diagnose ( clinically ) type 2 diabetes mellitus least 12 month ( 365 day ) prior day screen HbA1C equal 9.5 % base central laboratory analysis Smoker ( define subject smoke one cigarette equivalent per day ) able willing refrain smoking use nicotine substitute product inpatient period Surgery trauma significant blood loss ( 500 mL ) within last 90 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>